Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Morana Jovan-embiricos is Director at Kalaris Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jun 4, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
Jun 3, 20269,000disclosed Jun 4
DetailsOfficial recordMorana Jovan-embiricos bought shares on the open market in 2020, and has not bought since 2020 across 2 companies. Sales in 2 of the 7 years since 2020.
Morana Jovan-embiricos reported 2 open-market purchases and 17 sales since 2020; purchases in 2020.
| Year | Bought | Sold |
|---|---|---|
| 2022 | — | $712K3×3 trades |
| 2021 | — | $714K14×14 trades |
| 2020 | $49.3M2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Morana Jovan-embiricos bought shares on the open market in 2020, and has not bought since 2020 across 2 companies. Sales in 2 of the 7 years since 2020.
In SEC filings since 2020: the latest open-market purchase is from 2020; the latest open-market sale is from 2022.
2 companies: Cullinan Therapeutics (CGEM, 2022), Kalaris Therapeutics (KLRS, 2020–2021).
Morana Jovan-embiricos reported 2 open-market purchases and 14 sales here, 2020 to 2021.
Morana Jovan-embiricos reported 0 open-market purchases and 3 sales here, 2022.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
